Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
The identification of neurological diseases in their presymptomatic phase will be a fundamental aim in the coming years. This step is necessary both to optimize early diagnostics and to verify the effectiveness of experimental disease modifying drugs in the early stages of diseases. Among the biomar...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2021.672954/full |
| _version_ | 1819139788815466496 |
|---|---|
| author | Lorenzo Gaetani Lucilla Parnetti Paolo Calabresi Paolo Calabresi Massimiliano Di Filippo |
| author_facet | Lorenzo Gaetani Lucilla Parnetti Paolo Calabresi Paolo Calabresi Massimiliano Di Filippo |
| author_sort | Lorenzo Gaetani |
| collection | DOAJ |
| description | The identification of neurological diseases in their presymptomatic phase will be a fundamental aim in the coming years. This step is necessary both to optimize early diagnostics and to verify the effectiveness of experimental disease modifying drugs in the early stages of diseases. Among the biomarkers that can detect neurological diseases already in their preclinical phase, neurofilament light chain (NfL) has given the most promising results. Recently, its measurement in serum has enabled the identification of neurodegeneration in diseases such as multiple sclerosis (MS) and Alzheimer’s disease (AD) up to 6–10 years before the onset of symptoms. Similar results have been obtained in conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), up to 2 years before clinical onset. Study of the longitudinal dynamics of serum NfL has also revealed interesting aspects of the pathophysiology of these diseases in the preclinical phase. This review sought to discuss these very recent findings on serum NfL in the presymptomatic phase of neurological diseases. |
| first_indexed | 2024-12-22T11:28:14Z |
| format | Article |
| id | doaj.art-4653b46123af4ee8a9bd1c7ee2b4d043 |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-22T11:28:14Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-4653b46123af4ee8a9bd1c7ee2b4d0432022-12-21T18:27:41ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2021-05-011510.3389/fnins.2021.672954672954Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light ChainLorenzo Gaetani0Lucilla Parnetti1Paolo Calabresi2Paolo Calabresi3Massimiliano Di Filippo4Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, ItalySection of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, ItalyNeurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyNeuroscience Department, Università Cattolica del Sacro Cuore, Rome, ItalySection of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, ItalyThe identification of neurological diseases in their presymptomatic phase will be a fundamental aim in the coming years. This step is necessary both to optimize early diagnostics and to verify the effectiveness of experimental disease modifying drugs in the early stages of diseases. Among the biomarkers that can detect neurological diseases already in their preclinical phase, neurofilament light chain (NfL) has given the most promising results. Recently, its measurement in serum has enabled the identification of neurodegeneration in diseases such as multiple sclerosis (MS) and Alzheimer’s disease (AD) up to 6–10 years before the onset of symptoms. Similar results have been obtained in conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), up to 2 years before clinical onset. Study of the longitudinal dynamics of serum NfL has also revealed interesting aspects of the pathophysiology of these diseases in the preclinical phase. This review sought to discuss these very recent findings on serum NfL in the presymptomatic phase of neurological diseases.https://www.frontiersin.org/articles/10.3389/fnins.2021.672954/fullneurofilament light chainmultiple sclerosisAlzheimer’s diseasefrontotemporal lobar degenerationamyotrophic lateral sclerosispresymptomatic |
| spellingShingle | Lorenzo Gaetani Lucilla Parnetti Paolo Calabresi Paolo Calabresi Massimiliano Di Filippo Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain Frontiers in Neuroscience neurofilament light chain multiple sclerosis Alzheimer’s disease frontotemporal lobar degeneration amyotrophic lateral sclerosis presymptomatic |
| title | Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain |
| title_full | Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain |
| title_fullStr | Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain |
| title_full_unstemmed | Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain |
| title_short | Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain |
| title_sort | tracing neurological diseases in the presymptomatic phase insights from neurofilament light chain |
| topic | neurofilament light chain multiple sclerosis Alzheimer’s disease frontotemporal lobar degeneration amyotrophic lateral sclerosis presymptomatic |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2021.672954/full |
| work_keys_str_mv | AT lorenzogaetani tracingneurologicaldiseasesinthepresymptomaticphaseinsightsfromneurofilamentlightchain AT lucillaparnetti tracingneurologicaldiseasesinthepresymptomaticphaseinsightsfromneurofilamentlightchain AT paolocalabresi tracingneurologicaldiseasesinthepresymptomaticphaseinsightsfromneurofilamentlightchain AT paolocalabresi tracingneurologicaldiseasesinthepresymptomaticphaseinsightsfromneurofilamentlightchain AT massimilianodifilippo tracingneurologicaldiseasesinthepresymptomaticphaseinsightsfromneurofilamentlightchain |